OakChart

Perspective Therapeutics Inc

CATXHealthcare·Medical Devices·USA·Micro·AMEX·Nov 11 • 3:59 PM ET

0.8252+0.0388 (4.93%)
2026-11-12 01:21 CET
Market cap
89.77 USD m
Revenue, TTM
0.22 USD m
Net income, TTM
-122.91 USD m
Free cash flow, TTM
-138.93 USD m
EPS diluted, TTM
-1.25
P/E
-
Compare

Price

CATX against its 20, 50 and 200-day averages
2050200beatmiss
1.002.003.004.005.8M11.6MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CATXclose 0.8320-day 1.4050-day 2.20200-day 3.470.83

86.6% under the 52-week high of 6.16 on 29 Jan 2026. 52-week low 0.78 on 10 Nov 2026. Last 15 sessions, 207.7% high to low

Volume 3.59× normal · the line is the 50-bar volume average

Profile

CATX
52-week range, 1% of the way up
0.786.16

Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded by Michael K. Schultz in 1983 and is headquartered in Seattle, WA.

IndexRUT
Employees166
IPONov 10, 2005
Beta2.04
ATR, 14d0.17
Rel volume3.59
Short float9.44%
Insider own16.74%
Inst own85.60%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap99.65M
Enterprise Value-98.36M
Income-122.91M
Sales0.22M
Book/sh2.58
Cash/sh1.67
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees166
IPONov 10, 2005

Ratios

P/E-
Forward P/E-
PEG-
P/S452.93
P/B0.32
P/C0.49
P/FCF-
EV/EBITDA-
EV/Sales-447.11
Quick Ratio5.18
Current Ratio5.18
Debt/Eq0.01
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.25
EPS next Y-1.01
EPS next Q-0.27
EPS this Y30.27%
EPS next Y-2.95%
EPS next 5Y13.13%
EPS past 3/5Y-39.72% -22.26%
Sales past 3/5Y-56.57% -38.04%
EPS Y/Y TTM14.45%
Sales Y/Y TTM-79.53%
EPS Q/Q23.12%
Sales Q/Q-90.43%
EarningsNov 09 AMC
EPS/Sales Surpr.-11.25% -64.60%

Ownership

Insider Own16.74%
Insider Trans-2.64%
Inst Own85.60%
Inst Trans5.81%
ROA-37.28%
ROE-45.86%
ROIC-41.36%
Gross Margin-1932.27%
Oper. Margin-55315.00%
Profit Margin-55866.82%
SMA20-41.11%
SMA50-62.45%
SMA200-76.23%
Trades-

Technical

Shs Outstand114.16M
Shs Float95.04M
Short Float9.44%
Short Ratio3.67
Short Interest8.97M
52W High6.16 -86.60%
52W Low0.78 5.86%
Volatility14.02% 14.81%
ATR (14)0.17
RSI (14)22.79
Beta2.04
Rel Volume3.59
Avg Volume2.45M
Volume8,790,907

Performance

Perf Week-5.17%
Perf Month-63.65%
Perf Quarter-73.38%
Perf Half Y-78.40%
Perf YTD-69.99%
Perf Year-62.83%
Perf 3Y-64.89%
Perf 5Y-86.03%
Perf 10Y-85.65%
Recom1.27
Target Price9.46
Prev Close0.79
Price0.83
Change %4.93%

Analyst ratings

latest 10 of 14
DateActionAnalystRating changeTargetImplied
Oct 26, 2026DowngradeRRBC Capital MktsOutperform → Sector Perform$4+384.7%
Sep 18, 2026InitiatedWWilliam BlairOutperform
Aug 19, 2026InitiatedBBMO Capital MarketsOutperform$11+1,233.0%
Feb 19, 2026InitiatedPPiper SandlerOverweight$16+1,838.9%
Nov 24, 2025ResumedTTruistBuy$12+1,354.2%
Oct 10, 2025InitiatedBBTIG ResearchBuy$14+1,596.6%
Mar 13, 2025InitiatedHH.C. WainwrightBuy$10+1,111.8%
Mar 07, 2025InitiatedBScotiabankSector Outperform$15+1,717.7%
Nov 25, 2024DowngradeBBofA SecuritiesBuy → Neutral$24 → $5+505.9%
Oct 24, 2024InitiatedUUBSBuy$20+2,323.7%

Peers

Mkt cap
TickerCompanyMkt cap
AKTSAktis Oncology Inc947.76M
TLXTelix Pharmaceuticals Ltd ADR3.31B
LNTHLantheus Holdings Inc6.64B
ATNMActinium Pharmaceuticals Inc49.99M
MOLNMolecular Partners AG ADR118.47M
RADXRadiopharm Theranostics Ltd ADR12.87M
DRTSAlpha Tau Medical Ltd1.30B
CLRBCellectar Biosciences Inc11.44M
NVSNovartis AG ADR293.47B
NBTXNanobiotix ADR1.68B

Insider trading

9 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Lantheus Alpha Therapy, LLC10% OwnerSep 04 '26Sale3.15167,149526,05111,273,364Sep 08 04:51 PM
Lantheus Alpha Therapy, LLC10% OwnerSep 03 '26Sale3.1180,783250,89611,440,513Sep 08 04:51 PM
Lantheus Alpha Therapy, LLC10% OwnerSep 02 '26Sale3.1142,129131,21911,521,296Sep 04 05:00 PM
Lantheus Alpha Therapy, LLC10% OwnerAug 31 '26Sale3.1478,145245,61011,599,194Sep 04 04:58 PM
Lantheus Alpha Therapy, LLC10% OwnerSep 01 '26Sale3.1235,769111,57411,563,425Sep 04 04:58 PM
Lantheus Holdings, Inc.10% OwnerSep 01 '26Sale3.1235,769111,57411,563,425Sep 03 04:54 PM
Lantheus Holdings, Inc.10% OwnerAug 31 '26Sale3.1478,145245,61011,599,194Sep 02 04:36 PM
Hunt Jonathan RobertChief Accounting OfficerNov 13 '25Buy2.0311,00022,29559,800Nov 17 08:01 AM
Williamson Robert F IIIDirectorNov 12 '25Buy2.109,49819,9469,864Nov 14 08:00 AM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
VHTVanguard Health Care ETFAUM: 21.51B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
IBBiShares Biotechnology ETFAUM: 11.36B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VTWVVanguard Russell 2000 Value Index ETFAUM: 1.29B

News

latest 14 of 200
  • Perspective Therapeutics: Q3 Earnings Snapshot (Associated Press) -8.09%
  • Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2026 Results (GlobeNewswire)
  • Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026 (GlobeNewswire) +6.54%
  • Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-a-NET) in Advanced SSTR2 Expressing NETs (GlobeNewswire) -9.40%
  • Perspective's [212Pb]Bamzireotide Navoxetan (VMT-a-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs (GlobeNewswire) -28.76%
  • Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors (GlobeNewswire) +10.16%
  • Perspective Therapeutics Announces Acceptance of [212Pb]VMT-a-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium (GlobeNewswire)
  • Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026 (GlobeNewswire)
  • Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda (Pembrolizumab) in FAP-a Positive Solid Tumors (GlobeNewswire)
  • Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026 (GlobeNewswire)
  • Perspective Therapeutics: Q2 Earnings Snapshot (Associated Press) +6.00%
  • Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results (GlobeNewswire)
  • Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results (GlobeNewswire)
  • Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-a-NET in GEP-NETs (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-09-0.270-0.243-0.2700.020.0615
2026Q22026-08-10-0.220-0.251-0.2220.080.0915
2026Q12026-05-11-0.250-0.294-0.2530.080.1614
2025Q42026-03-16-0.510-0.363-0.5040.040.2316
2025Q32025-11-10-0.350-0.321-0.3500.210.2413
2025Q22025-08-13-0.300-0.293-0.2890.290.2013
2025Q12025-05-12-0.250-0.305-0.2510.340.1411
2024Q42025-03-26-0.574-0.268-0.5680.230.2814
2024Q32024-11-12-0.210-0.213-0.2140.370.299
2024Q22024-08-12-0.180-0.206-0.1760.530.187
2024Q12024-05-15-0.200-0.280-0.2480.330.375
2023Q32023-11-14---0.3692.19--
2023Q42023-08-11-0.400--0.3971.50--
2023Q22023-02-16---0.0231.84--
2023Q12022-11-10---0.0291.72--
2022Q42022-09-28---0.1462.51--

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-0.800-0.833-0.7697.317.33
2020FY-0.500-0.433-0.5119.6810.10
2021FY-0.300-0.267-0.32710.0510.03
2022FY-0.500-0.500-0.50010.8011.14
2023FY-1.700-1.300-1.7381.437.86
2024FY-1.230-0.852-1.2311.451.35
2025FY-1.410-1.233-1.4000.881.06
2026FY--0.983--0.27
2027FY--1.012--0.33
2028FY--0.924--0.83
2029FY--0.681--49.99
2030FY--0.386--93.75

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-1011010.060.000.21
2026Q4S2026-11-0911000.060.000.21
2026Q4S2026-10-2811000.060.000.21
2026Q4S2026-10-2511010.060.000.21
2026Q4S2026-10-2311130.060.000.21
2026Q4S2026-09-0610130.070.000.21
2026Q4S2026-08-2711130.080.000.21
2026Q4S2026-08-1412130.070.000.21
2026Q4S2026-08-1212120.090.000.40
2026Q4S2026-08-1112130.090.000.40
2026Q4S2026-07-2612010.100.000.40
2026Q4S2026-06-0212230.100.000.40
2026Q4S2026-05-2912240.100.000.40
2026Q4S2026-05-1212230.110.000.40

Estimate history

EPS, annual-0.9-1.1-1.217-0.769-0.511-0.327-1.738-1.231-1.397-1.2478
Period201620172018201920202021202320242025TTM
EPS, quarterly-0.214-0.568-0.251-0.289-0.35-0.504-0.253-0.222-0.269
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual4.7694.7615.9237.3149.6810.0531.4341.4540.8840.22
Period201620172018201920202021202320242025TTM
Sales, quarterly0.3690.2340.3420.290.2090.0430.0760.0810.02
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual5.5015.5025.6336.7396.8914.19228.18170.67174.338114.161
Period201620172018201920202021202320242025MRQ
Shares, quarterly67.56370.67174.05174.26374.33874.338114.018114.086114.161
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2021FY2020FY2019FY2018FY
Total Revenue0.220.881.451.43-10.059.687.315.92
Cost of Goods Sold Incl. D&A4.473.252.311.02-4.934.564.274.08
Gross Profit-4.25-2.37-0.850.41-5.125.123.051.84
Selling, General and Administrative Excl. Other117.44101.2065.9441.35-8.568.678.328.57
Research and Development87.4470.9639.3320.33-1.431.131.471.75
Other Operating Expense0.000.000.000.00-0.000.000.000.00
Operating Income-121.69-103.56-66.80-40.94--3.44-3.55-5.28-6.73
Interest Expense0.400.380.050.08-0.000.000.000.00
Unusual Expense10.0010.0024.060.00-0.00-0.070.000.00
Net Income Before Taxes-123.90-104.43-80.43-40.11--3.39-3.45-5.14-6.70
Income Taxes-0.79-0.79-2.10-2.65-0.000.000.000.00
Consolidated Net Income-123.10-103.64-78.33-37.45--3.39-3.45-5.14-6.70
Net Income From Continuing Operations-123.10-103.64-78.33-37.45--3.39-3.45-5.14-6.70
Net Income-122.91-103.12-79.28-46.51--3.39-3.46-5.16-6.71
EPS (Recurring)-0.96-1.30-0.97-1.74--0.33-0.52-0.77-1.22
EPS (Basic, Before Extraordinaries)-1.25-1.40-1.23-1.74--0.33-0.51-0.77-1.22
EPS (Diluted)-1.25-1.40-1.23-1.74--0.33-0.51-0.77-1.22
EBITDA-117.22-100.31-64.49-39.92--3.22-3.33-5.06-6.57
Non-Operating Income (Expense)8.199.5110.480.92-0.050.030.130.03
Other After Tax Adjustments0.000.000.000.00-0.000.000.000.00
Stock Option Compensation Expense9.157.084.122.48-0.390.490.420.40
Price To Sales Ratio1,509.35229.62141.3575.03-8.243.883.764.19
Gross Margin-1,932.27-267.76-58.6028.80-50.9452.9341.6631.10
Operating Margin-55,315.00-11,715.38-4,594.02-2,855.02--34.19-36.66-72.16-113.61
Net Margin-55,866.82-11,665.27-5,452.48-3,243.24--33.72-35.71-70.48-113.30
Shares Outstanding114.1674.3470.6728.18-14.196.896.745.63
Market Capitalization89.7789.77215.601,127.90-1,128.75375.80276.09247.95

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.020.080.080.040.210.290.340.23
Cost of Goods Sold Incl. D&A1.191.141.131.010.780.730.730.71
Gross Profit-1.17-1.06-1.05-0.97-0.57-0.44-0.39-0.47
Selling, General and Administrative Excl. Other33.1528.2027.2328.8627.3023.6021.4420.42
Research and Development24.8820.4020.2521.9119.5615.8913.6012.17
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-34.32-29.26-28.28-29.83-27.86-24.04-21.83-20.89
Interest Expense0.160.070.100.060.070.120.13-
Unusual Expense0.000.000.0010.000.000.000.0024.06
Net Income Before Taxes-32.44-26.98-26.19-38.28-25.97-22.00-18.18-42.21
Income Taxes0.000.000.00-0.790.000.000.00-2.10
Consolidated Net Income-32.44-26.98-26.19-37.49-25.97-22.00-18.18-40.11
Net Income From Continuing Operations-32.44-26.98-26.19-37.49-25.97-22.00-18.18-40.11
Net Income-32.44-26.79-26.19-37.49-25.97-21.48-18.18-40.17
EPS (Recurring)-0.27-0.22-0.25-0.41-0.35-0.29-0.25-0.33
EPS (Basic, Before Extraordinaries)-0.27-0.22-0.25-0.50-0.35-0.29-0.25-0.57
EPS (Diluted)-0.27-0.22-0.25-0.50-0.35-0.29-0.25-0.57
EBITDA-33.13-28.12-27.16-28.82-27.09-23.31-21.10-20.19
Non-Operating Income (Expense)2.042.352.201.611.962.163.782.75
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.133.052.550.432.162.402.100.96
Price To Sales Ratio1,509.351,005.92699.08231.26237.06206.78104.77155.05
Gross Margin-5,865.00-1,308.64-1,381.58-2,251.16-270.81-152.76-114.04-202.99
Operating Margin-171,610.00-36,120.99-37,211.84-69,376.74-13,330.62-8,289.31-6,383.63-8,929.49
Net Margin-162,210.00-33,069.14-34,459.21-87,186.05-12,425.36-7,408.62-5,314.91-17,166.24
Shares Outstanding114.16114.09114.0274.3474.3474.2674.0570.67
Market Capitalization89.77388.90475.10204.43254.72255.35157.73215.60

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments144.74226.929.24-63.832.395.333.428.97
Short Term Receivables1.041.481.18-2.042.081.241.230.79
Inventories0.000.000.00-0.980.650.530.490.32
Other Current Assets2.612.766.42-0.450.400.220.290.20
Total Current Assets148.39231.1616.84-67.305.517.325.4510.29
Net Property, Plant & Equipment78.1059.546.32-2.732.741.611.311.05
Total Investments and Advances0.120.130.32-0.180.180.180.180.18
Intangible Assets40.1650.2174.42-0.130.140.160.200.23
Deferred Tax Assets7.379.008.87------
Other Assets0.210.070.00-0.080.140.150.320.51
Total Assets274.35350.11106.76-70.428.709.427.4612.27
Short Term Debt Incl. Current Port. of LT Debt0.681.010.10-0.250.240.000.000.00
Accounts Payable20.5110.346.11-0.730.650.681.390.63
Other Current Liabilities7.496.889.46-0.820.690.440.440.48
Total Current Liabilities28.6818.2315.66-1.801.571.121.831.11
Long Term Debt2.573.052.46-0.520.770.000.000.00
Provision for Risks Charges0.000.000.00-0.610.580.620.590.56
Deferred Tax Liabilities9.0711.5013.46------
Other Liabilities26.9926.660.00-0.080.060.000.000.00
Total Liabilities67.3159.4431.58-3.012.981.742.421.67
Non-Equity Reserves0.000.000.00-0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.00-0.000.000.000.000.00
Common Equity207.03290.6775.18-67.415.727.685.0310.60
Total Shareholders Equity207.03290.6775.18-67.415.727.685.0310.60
Accumulated Minority Interest0.000.000.00-0.000.000.000.000.00
Total Equity207.03290.6775.18-67.415.727.685.0310.60
Total Liabilities & Stockholders Equity274.35350.11106.76-70.428.709.427.4612.27
Book Value Per Share2.794.112.67-4.750.831.140.891.93
Tangible Book Value Per Share2.243.400.03-4.740.811.120.861.89
Full-Time Employees166140119-6753433836
Price to Book Ratio0.300.661.04-1.686.693.213.753.24
Return on Assets-33.19-34.29-43.76--8.56-38.03-60.96-67.94-40.58
Return on Equity-41.65-42.82-54.90--9.26-51.42-80.94-85.72-45.64
Return on Invested Capital-49.20-26.99-59.91--4.99-53.08-66.98-133.20-58.12
Quick Ratio5.1712.681.07-36.833.096.052.709.01
Current Ratio5.1712.681.07-37.373.506.532.979.30

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2021FY2020FY2019FY2018FY
Net Income-122.91-103.12-79.28-46.51--3.39-3.45-5.14-6.70
Depreciation4.473.252.311.02-0.220.220.220.16
Other Funds (Non Cash)19.1116.5028.968.93-0.400.420.400.61
Funds from Operations-100.12-84.17-50.11-39.21--2.77-2.81-4.53-5.93
Extraordinary Item0.000.000.000.00-0.000.000.000.00
Changes in Working Capital-8.011.6831.812.30--0.07-0.83-0.520.22
Cash from Operating Activities-108.13-82.48-18.29-36.91--2.84-3.64-5.05-5.71
Capital Expenditures-30.80-12.88-54.49-1.07--0.41-0.29-0.46-0.35
Net Assets From Acquisitions0.000.000.002.70-0.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.340.00-0.000.000.030.00
Purchase or Sale of Investments-11.5154.11-164.7822.76-0.000.000.822.21
Purchase of Investments-240.62-119.84-243.510.00-0.000.00-4.72-4.05
Sale Or Maturity of Investments229.11173.9578.7322.76-0.000.005.556.27
Other Uses0.000.000.00-0.02-0.000.000.000.00
Other Sources0.000.000.000.00-0.000.000.00-
Cash from Investing Activities-42.2741.23-218.9324.37--0.41-0.290.401.86
Cash Dividends Paid0.000.000.000.00--0.01-0.01-0.01-0.01
Change in Capital Stock164.7310.36289.430.85-64.691.007.380.53
Repurchase of Common Pref Stock0.000.000.000.00-0.000.000.000.00
Sale of Common Pref Stock164.7310.36289.430.85-64.691.007.380.53
Proceedsfrom Stock Options164.099.99275.810.30-56.380.877.370.48
Issuance or Reduction of Debt, Net-0.06-0.05-0.05-0.07-0.000.000.000.00
Change in Long Term Debt-0.06-0.05-0.05-0.07-0.000.000.000.00
Issuance of Long Term Debt0.000.000.000.00-0.000.000.000.00
Reduction of Long Term Debt-0.06-0.05-0.05-0.07-0.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.00-0.000.000.000.00
Other Financing Activities Uses0.000.000.000.00-0.000.000.000.00
Cash from Financing Activities164.6710.30289.380.79-64.680.997.370.52
Net Change in Cash14.28-30.9552.16-11.76-61.44-2.932.73-3.33
Free Cash Flow-138.93-95.37-72.71-37.98--3.22-3.91-5.49-6.05
Preferred Dividends (Cash Flow)-0.000.000.00--0.01-0.01-0.01-0.01
Deferred Taxes & Investment Tax Credit--0.79-2.10-2.65-0.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments201.69236.88270.93144.74174.14191.58
Short Term Receivables0.010.270.061.040.180.23
Inventories0.000.000.000.000.000.00
Other Current Assets3.584.384.372.614.184.16
Total Current Assets205.28241.52275.35148.39178.50195.96
Net Property, Plant & Equipment119.87109.9994.9378.1065.8964.37
Total Investments and Advances0.000.000.000.120.000.00
Intangible Assets40.0040.0040.0040.1650.0050.00
Deferred Tax Assets---7.37--
Other Assets0.530.510.490.210.440.40
Total Assets365.68392.02410.77274.35294.82310.73
Short Term Debt Incl. Current Port. of LT Debt1.181.151.120.680.760.90
Accounts Payable31.6229.4226.4820.5112.956.85
Other Current Liabilities6.815.973.887.496.915.24
Total Current Liabilities39.6036.5431.4928.6820.6212.99
Long Term Debt2.502.813.112.572.552.67
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities1.701.701.709.072.502.50
Other Liabilities27.2027.1127.0426.9926.9426.88
Total Liabilities71.0068.1663.3367.3152.6145.03
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity294.68323.86347.44207.03242.22265.69
Total Shareholders Equity294.68323.86347.44207.03242.22265.69
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity294.68323.86347.44207.03242.22265.69
Total Liabilities & Stockholders Equity365.68392.02410.77274.35294.82310.73
Book Value Per Share2.582.843.052.793.263.58
Tangible Book Value Per Share2.232.492.702.242.592.90
Full-Time Employees---166--
Price to Book Ratio0.301.201.370.840.960.89
Return on Assets-37.28-33.19-30.17-33.19-30.98-27.39
Return on Equity-45.86-39.57-35.33-41.65-37.24-31.45
Return on Invested Capital-10.92-8.20-7.47-17.89-10.61-8.01
Quick Ratio5.186.618.755.178.6615.09
Current Ratio5.186.618.755.178.6615.09

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-32.44-26.79-26.19-37.49-25.97-21.48
Depreciation1.191.141.131.010.780.73
Other Funds (Non Cash)2.622.422.1411.931.611.71
Funds from Operations-28.63-23.22-22.92-25.34-23.58-19.04
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-2.722.57-8.550.697.29-0.91
Cash from Operating Activities-31.35-20.65-31.47-24.66-16.29-19.95
Capital Expenditures-4.55-14.22-6.86-5.21-2.03-1.06
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments28.2929.23-102.6933.6616.025.33
Purchase of Investments-34.05-35.62-150.34-20.61-32.13-44.49
Sale Or Maturity of Investments62.3464.8547.6454.2848.1549.82
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities23.7315.02-109.5528.5413.994.26
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.190.16164.380.000.230.14
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.190.16164.380.000.230.14
Proceedsfrom Stock Options0.00164.090.000.000.000.00
Issuance or Reduction of Debt, Net-0.01-0.01-0.01-0.01-0.01-0.01
Change in Long Term Debt-0.01-0.01-0.01-0.01-0.01-0.01
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.01-0.01-0.01-0.01-0.01-0.01
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.170.15164.36-0.010.210.13
Net Change in Cash-7.45-5.4823.343.87-2.09-15.56
Free Cash Flow-35.89-34.84-38.33-29.87-18.28-20.98

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-309.44%9.0M95.0M2.02M
2026-10-1517.55%16.7M95.0M1.56M
2026-09-3017.44%16.6M95.0M1.62M
2026-09-1524.65%22.8M92.5M1.62M
2026-08-3125.33%23.4M92.2M1.64M
2026-08-1425.02%23.0M92.1M1.67M
2026-07-3126.03%23.5M90.2M1.73M
2026-07-1525.26%22.8M90.2M1.86M
2026-06-3025.20%22.7M90.2M1.61M
2026-06-1515.12%13.6M90.2M1.44M
2026-05-2914.15%12.8M90.2M1.40M
2026-05-1513.99%12.6M90.2M1.55M
2026-04-3014.03%13.0M92.6M2.08M
2026-04-1514.77%13.7M92.6M3.39M
2026-03-3115.26%14.1M92.6M3.52M
2026-03-1310.91%10.1M92.6M3.37M
2026-02-2710.42%9.6M92.5M3.38M
2026-02-1310.39%9.6M92.5M3.43M
2026-01-3015.47%9.5M61.7M2.91M
2026-01-1513.32%8.2M61.7M1.68M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.001.000.000.0000.000.000.0000.0000.000
call1.000.001.000.000.0000.000.000.0000.0000.000
call1.500.000.250.050.00020.000.000.746-0.0280.000
call2.000.001.000.0013.0520.000.000.738-0.0280.000
call2.500.000.100.035.4384780.000.186-0.0110.000
call5.000.001.000.0510.9072820.000.419-0.0300.000
call7.500.001.000.0011.6160.000.000.409-0.0300.001
put0.500.001.000.000.0000.000.000.0000.0000.000
put1.000.001.000.000.0000.000.000.0000.0000.000
put1.500.151.150.0012.7280.000.00-0.449-0.0220.001
put2.000.701.700.0015.0170.000.00-0.474-0.0260.001
put2.501.102.101.0013.3191.000.00-0.814-0.0100.000
put5.003.604.600.0015.4280.000.00-0.843-0.0120.000
put7.506.207.200.0018.8880.000.00-0.854-0.0130.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13GSEC
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-11-068-KCurrent report2026-11-06SEC
2026-11-068-KCurrent report2026-11-05SEC
2026-10-238-KCurrent report2026-10-23SEC
2026-10-088-KCurrent report2026-10-08SEC
2026-10-018-KCurrent report2026-10-01SEC
2026-09-23SCHEDULE 13D/ASEC
2026-09-148-KCurrent report2026-09-14SEC
2026-09-084Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-088-KCurrent report2026-09-08SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-04SCHEDULE 13D/ASEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-108-KCurrent report2026-08-10SEC
2026-08-07SCHEDULE 13GSEC
2026-08-038-KCurrent report2026-08-03SEC
2026-07-29SCHEDULE 13GSEC
2026-07-20SCHEDULE 13GSEC
2026-07-018-KCurrent report2026-07-01SEC
2026-06-30SCHEDULE 13GSEC
2026-06-018-KCurrent report2026-06-01SEC
2026-05-278-KCurrent report2026-05-27SEC
2026-05-228-KCurrent report2026-05-21SEC
2026-05-12SCHEDULE 13G/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-09001.13M5
2026-0800491.22K2
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-1142.24K200

Institutional holders

Manager% owned
BlackRock, Inc.8.32%
TCG Crossover Management, LLC6.94%
Commodore Capital LP5.56%
Avidity Partners Management LP5.52%
STATE STREET CORP5.31%
MILLENNIUM MANAGEMENT LLC4.31%
Nantahala Capital Management, LLC4.08%
VANGUARD CAPITAL MANAGEMENT LLC3.89%
Affinity Asset Advisors, LLC3.70%
CITADEL ADVISORS LLC3.34%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF3.54%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.91%
iShares Russell 2000 ETF2.32%
Fidelity Small Cap Index Fund0.99%
VANGUARD EXTENDED MARKET INDEX FUND0.89%
iShares Russell 2000 Value ETF0.86%
iShares Biotechnology ETF0.56%
VANGUARD RUSSELL 2000 INDEX FUND0.52%
BlackRock Advantage Small Cap Core Fund0.52%
Schwab U.S. Small-Cap ETF0.35%

OakChart. CATX. Cached 15 minutes.